New Data Show Statistically Greater Improvements in Clinical Outcomes with Subcutaneous Infliximab, Compared to Intravenous Infliximab, in Patients With Rheumatoid Arthritis
Presented today at EULAR 2022, data from a new post-hoc analysis show a statistically significant difference in clinical outcomes with subcutaneous (SC) infliximab compared to intravenous (IV) infliximab at week 30, using conservative missing imputation methods Data also show that differences in efficacy outcomes between SC and IV infliximab groups reduced at week 54, after … [Read more…]